Article Text

other Versions

PDF
Termination of damaged protein repair defines the occurrence of symptoms in carriers of the m.3243A>G tRNALeu mutation.
  1. Rudy van Eijsden (rudy.vaneijsden{at}gen.unimaas.nl)
  1. Maastricht University, Netherlands
    1. Lars Eijssen (l.eijssen{at}bigcat.unimaas.nl)
    1. Maastricht University, Netherlands
      1. Patrick Lindsey (p.lindsey{at}gen.unimaas.nl)
      1. Maastricht University, Netherlands
        1. Caroline van den Burg (cvdburg{at}gen.unimaas.nl)
        1. Maastricht University, Netherlands
          1. Elly de Wit (l.e.a.dewit{at}erasmusmc.nl)
          1. Erasmus Medical Center, Netherlands
            1. Estella Rubio-Gozalbo (mrub{at}paed.azm.nl)
            1. Maastricht University Hospital, Netherlands
              1. Christine de Die (christine.dedie{at}gen.unimaas.nl)
              1. Maastricht University Hospital, Netherlands
                1. Torik Ayoubi (torik.ayoubi{at}gen.unimaas.nl)
                1. Maastricht University, Netherlands
                  1. Willem Sluiter (w.sluiter{at}erasmusmc.nl)
                  1. Erasmus Medical Center, Netherlands
                    1. Irene de Coo (i.decoo{at}erasmusmc.nl)
                    1. Erasmus Medical Center, Netherlands
                      1. Hubert Smeets (bert.smeets{at}molcelb.unimaas.nl)
                      1. Maastricht University, Netherlands

                        Abstract

                        The m.3243A>G mutation in the mitochondrial tRNALeu(UUR) gene is an example of a mutation causing a very heterogeneous phenotype. It is the most frequent cause (80%) of the MELAS syndrome (Mitochondrial Myopathy, Encephalopathy, Lactic Acidosis and Stroke-like episodes), but it can also lead in addition or separately to type 2 diabetes, deafness, renal tubulopathy and/or cardiomyopathy. To identify pathogenic processes induced by this mutation, we compared global gene expression levels of muscle biopsies from affected and unaffected mutation carriers with controls. Gene expression changes were relatively subtle. In the a symptomatic group 200 transcripts were up- and 12 were down-regulated, whereas in the symptomatic groups this was 15 and 52 respectively. In the a symptomatic group, oxidative phosphorylation (OXPHOS) complex I and IV genes were induced. Protein turnover and apoptosis were elevated, most likely due to the formation of dysfunctional and reactive oxygen species (ROS) damaged proteins. These processes returned to normal in symptomatic patients. Components of the complement system were up-regulated in both groups, but the strongest in the symptomatic group, which might indicate muscle regeneration. Most likely protein damage and OXPHOS dysfunction stimulate repair (protein regeneration) and metabolic adaptation (OXPHOS). In a symptomatic individuals these processes suffice to prevent the occurrence of symptoms. However, in affected individuals the repair process terminates, presumably because of excessive damage, and switches to muscle regeneration, as indicated by a stronger complement activation. This switch leaves increasingly damaged tissue in place and muscle pathology becomes manifest. Therefore, the expression of complement components might be a marker for the severity and progression of MELAS clinical course.

                        Statistics from Altmetric.com

                        Request permissions

                        If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.